ArticleJournal of managed care & specialty pharmacy2024

Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.

Shao-Hsuan Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.